CN103110825B - Medicinal composition for treating diabetes and preparation method thereof - Google Patents
Medicinal composition for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN103110825B CN103110825B CN201310053437.7A CN201310053437A CN103110825B CN 103110825 B CN103110825 B CN 103110825B CN 201310053437 A CN201310053437 A CN 201310053437A CN 103110825 B CN103110825 B CN 103110825B
- Authority
- CN
- China
- Prior art keywords
- hours
- slow fire
- thick paste
- treatment
- herba dendrobii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating diabetes and a preparation method thereof. The composition comprises mulberry twig, mantis egg-case, cornel and dendrobe. The medicinal composition disclosed by the invention is prepared through the steps such as decocting, filtering, concentrating, drying and the like, and can be prepared into clinically acceptable tablets, capsules, granules, pills or oral liquids by adding conventional auxiliary materials. The medicinal composition disclosed by the invention has the effects of blood sugar reduction, blood fat reduction, blood rheology change, oxidation resistance and the like, has favorable treatment action and remarkable effect on diabetes, and has no toxic or side effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of diabetes.
Background technology
Diabetes are the commonly encountered diseases that caused by h and E factor interaction, clinically take hyperglycemia as outstanding feature, and common sympton has polydipsia, polyuria, polyphagia and becomes thin etc.Diabetes can cause the infringement of health multisystem.Cause that the absolute or relative hyposecretion of insulin and target tissue cell reduce insulin sensitivity, cause a series of metabolism disorder syndromes such as protein, fat, power and water Xie Zhi, wherein take hyperglycemia as outstanding feature.The multiple teenager of being born in of type i diabetes, relies on exogenous insulin and supplements to sustain life; During type ii diabetes is more common in, old people, show as body responsive not to insulin, i.e. insulin resistant.At present the medicine for the treatment of diabetes is a lot, Western medicine especially, but side effect is large.Chinese patent medicine effect is remarkable not.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of diabetes.
The object of the invention is also to provide a kind of preparation method for the treatment of the pharmaceutical composition of diabetes.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Ramulus Mori 20-60 weight portion Ootheca Mantidis 40-120 weight portion
Fructus Corni 20-60 weight portion Herba Dendrobii 10-30 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 40 weight portion Ootheca Mantidis 80 weight portions
Fructus Corni 40 weight portion Herba Dendrobii 20 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 25 weight portion Ootheca Mantidis 115 weight portions
Fructus Corni 25 weight portion Herba Dendrobii 28 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Ramulus Mori 55 weight portion Ootheca Mantidis 45 weight portions
Fructus Corni 55 weight portion Herba Dendrobii 12 weight portions.
Pharmaceutical composition of the present invention adds conventional adjuvant to make the tablet of clinical acceptance, capsule, granule, pill or oral liquid according to common process.
The preparation method of pharmaceutical composition of the present invention is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added to water 10-20 and doubly measure, soak 24-48 hour; With slow fire boiling 1-3 time, decoct 1-3 hour at every turn, medicinal liquid is leached, collect standby; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 5-10 minute, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 5-15 hour, the powder that gets dry extract, adds conventional adjuvant pharmaceutically to make tablet, capsule, granule, oral liquid, injection or pill dried cream powder.
The preferred preparation method of pharmaceutical composition of the present invention is: Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 15 times of amounts of water, soak 36 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to thick paste shape, add 5 times amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry at 50 ℃, and dry grain is after 14 mesh sieve granulate, granulation agent.
Pharmaceutical composition of the present invention has the effects such as blood sugar lowering, blood fat reducing, the change of change blood flow and antioxidation, and treatment diabetes are had to good therapeutical effect, and effect is remarkable, has no side effect.
Experimental example is used for further illustrating the present invention below, but is not limited to the present invention.
One, experimental example
1, clinical observation
Treatment group 1 anthology invention Granules in Treating diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Treatment group 2 anthology invention tablet in treatment diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Treatment group 3 anthology invention capsules treatments diabetics 50 examples, male's 20 examples wherein, women's 30 examples.
Matched group is selected Ramulus Mori granule, is produced treatment diabetics 50 examples, male's 20 examples wherein, women's 30 examples by Qingdao Haier Pharmaceutical Co., Ltd.
Above patient all meets ADA diabetes diagnosis standard in 2010.
2, medicament selection
Treatment group 1: granule of the present invention (according to embodiment 1 method preparation), treat three courses for the treatment of (10 days courses for the treatment of), 3g/ bag, one day 3 times, one time 1 bag.
Treatment group 2: tablet of the present invention (according to embodiment 2 methods preparations), treat three courses for the treatment of (10 days courses for the treatment of), 0.3g/ sheet, one day 3 times, one time 1.
Treatment group 3: capsule of the present invention (according to embodiment 3 methods preparations), treat three courses for the treatment of (10 days courses for the treatment of), 0.3g/ grain, one day 3 times, one time 1.
Matched group: Ramulus Mori granule, by Qingdao Haier Pharmaceutical Co., Ltd, produced, treat three courses for the treatment of (10 days courses for the treatment of), 3g/ bag, 3 times on the one, one time 1 bag.
3, diagnostic criteria
ADA diabetes diagnosis standard in 2010:
1, glycosated Hb A 1c >=6.5%.
2, fasting glucose FPG >=7.0mmol/l.Being defined as on an empty stomach at least interior empty calory of 8h takes in.
3,2h blood glucose >=11.1mmol/l during oral glucose tolerance test.
4, at the patient with typical hyperglycemia or hyperglycemia crisis symptom, random blood sugar >=11.1mmol/l.
5,, when without clear and definite hyperglycemia, should carry out confirmation standard 1～3 by duplicate detection.
4, criterion of therapeutical effect
Effective: after treatment, symptom disappears substantially, fasting glucose < 7.2mmol/L, (130mg/dl), 2 hours blood glucose < 8.3mmol/L(150mg/dl after the meal), twenty-four-hour urine sugar total amount < 10.0g, or blood glucose, twenty-four-hour urine sugar total amount are treated front decline more than 30%.
Effective: after treatment, symptom is obviously improved, fasting glucose < 8.3mmol/L(150mg/dl), 2 hours blood glucose < 10.0mmol/L(180mg/dl after the meal), twenty-four-hour urine sugar total amount < 25.0g, or blood glucose, twenty-four-hour urine sugar total amount are treated front decline more than 10%.
Invalid: after treatment, symptom is not improved, blood glucose, glucose in urine decline and do not reach above-mentioned standard.
Table 1 treatment group 1 Clinical Laboratory efficacy evaluation (n=50)
Table 2 treatment group 2 Clinical Laboratory efficacy evaluations (n=50)
Table 3 treatment group 3 Clinical Laboratory efficacy evaluations (n=50)
Table 4 matched group Clinical Laboratory efficacy evaluation (n=50)
6, conclusion
Treatment group 1, treatment group 2, treatment group 3 are treated respectively three courses for the treatment of (10 days each courses for the treatment of) with matched group, treatment group 1 fasting glucose and after the meal 2 hours blood glucose total effective rates are 98%, treatment group 2 fasting glucose and after the meal 2 hours blood glucose total effective rates are 94%, treatment group 3 fasting glucose and after the meal 2 hours blood glucose total effective rates are 92%, matched group fasting glucose and after the meal 2 hours blood glucose total effective rates 84%.Treatment group 1 therapeutic effect of the present invention is best, and treatment group 1 of the present invention, treatment group 2 and treatment 3 are obviously better than matched group.
7, discuss
In pharmaceutical composition of the present invention, Ramulus Mori is the twig of moraceae plants Mulberry, has wind-damp dispelling, and the effect of profit joint row aqueous vapor, cures mainly anemofrigid-damp arthralgia, spasm of the limbs, beriberi edema, human body pruritus due to wind pathogen.Ootheca Mantidis is the dry ootheca of Mantidae insecticide Chinese mantid, maculated mantis or huge axe dung beetle, and Ootheca Mantidis has controlling nocturnal emission with astringent drugs reducing urination, the effect of reinforcing the kidney and supporting YANG, and for emission due to deficiency of the kidney, premature ejaculation, sexual impotence, nebulousurine, leukorrhagia.Fructus Corni is machaka or dungarunga, has liver and kidney tonifying, restrains astringent or styptic treatment for spontaneous sweatingly, and controlling nocturnal emission with astringent drugs reducing urination, leukorrhagia stopping only collapse, hidroschesis, also have promoting the production of body fluid to quench thirst effect; Be used for the treatment of soreness of waist and knee joint dizziness and tinnitus, forgetful emission and spermatorrhea, enuresis frequent micturition, bleeding not during menses menoxenia, profuse sweating collapse, interior-heat is quenched one's thirst.Herba Dendrobii is the stem of orchid Dendrobium nobile or its multiple congener, has nourishing YIN and clearing away heat, lung moistening nourishing the stomach, strengthening the tendons and bones.Cure mainly the diseases such as consumption of body fluid caused by febrile disease, xerostomia excessive thirst, stomachache retch, the few expectorant of cough.The all medicine merging of crude drug of the present invention have the effects such as blood sugar lowering, blood fat reducing, the change of change blood flow and antioxidation, and treatment diabetes are had to good therapeutical effect, and effect is remarkable, has no side effect.
Embodiment 1 granule
Ramulus Mori 40kg Ootheca Mantidis 80kg
Fructus Corni 40kg Herba Dendrobii 20kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 15 times of amounts of water, soak 36 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to thick paste shape, add 5 times amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry at 50 ℃, and dry grain, after 14 mesh sieve granulate, is packed and be get final product.Granule specification: 3g/ bag, one day 3 times, one time 1 bag.
Embodiment 2 tablets
Ramulus Mori 25kg Ootheca Mantidis 115kg
Fructus Corni 25kg Herba Dendrobii 28kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 15 times of amounts of water, soak 36 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, crosses 80 mesh sieves by dried cream powder, adds starch to mix, then adds 10% starch slurry to make soft material, the granulation of sieving, adds magnesium stearate to mix rear tabletting, obtains.Wherein the ratio of mixture A and starch, 10% starch slurry, magnesium stearate is 10:1:0.5:0.05.Tablet specification is: 0.3g/ sheet, every day three times, each 1.
Embodiment 3 capsules
Ramulus Mori 55kg Ootheca Mantidis 45kg
Fructus Corni 55kg Herba Dendrobii 12kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 12 times of amounts of water, soak 38 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder with above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, the weight ratio that is 1:0.5 by dried cream powder and starch adds adjuvant, granulation, 50 ℃ are dried, after granulate, are sub-packed in capsule.Capsule specification: 0.2g/ grain, one day 3 times, one time 1.
Claims (4)
1. a pharmaceutical composition for the treatment of diabetes, is characterized in that:
Ramulus Mori 40kg Ootheca Mantidis 80kg
Fructus Corni 40kg Herba Dendrobii 20kg;
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 15 times of amounts of water, soak 36 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, adds dried cream powder 75% ethanol of 2 times of amounts again, be evaporated to thick paste shape, add 5 times amount Icing Sugar, add 70% ethanol a little, make soft material, crossing 14 mesh sieves granulates, wet granular is dry at 50 ℃, and dry grain, after 14 mesh sieve granulate, is packed and be get final product.
2. a pharmaceutical composition for the treatment of diabetes, is characterized in that:
Ramulus Mori 25kg Ootheca Mantidis 115kg
Fructus Corni 25kg Herba Dendrobii 28kg;
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 15 times of amounts of water, soak 36 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder and above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, crosses 80 mesh sieves by dried cream powder, adds starch to mix, then adds 10% starch slurry to make soft material, the granulation of sieving, adds magnesium stearate to mix rear tabletting, obtains.
3. a pharmaceutical composition for the treatment of diabetes, is characterized in that:
Ramulus Mori 55kg Ootheca Mantidis 45kg
Fructus Corni 55kg Herba Dendrobii 12kg.
Ramulus Mori, Fructus Corni and Herba Dendrobii are added to 12 times of amounts of water, soak 38 hours; With slow fire boiling 2 times, decoct for the first time 2 hours, medicinal liquid is leached stand-by, add for the second time 10 times of water gagings, with slow fire boiling 1 hour, medicinal liquid is leached stand-by; Merge secondary medical filtration, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1:1.25-1.35, standby; Ootheca Mantidis is cleaned, with slow fire, fried 8 minutes, wear into fine powder with above-mentioned thick paste mixes, low-temperature bake 10 hours, the powder that gets dry extract, the weight ratio that is 1:0.5 by dried cream powder and starch adds adjuvant, granulation, 50 ℃ are dried, after granulate, are sub-packed in capsule.
4. the application of the pharmaceutical composition as described in one of claim 1-3 in the medicine of preparation treatment diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310053437.7A CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310053437.7A CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110825A CN103110825A (en) | 2013-05-22 |
| CN103110825B true CN103110825B (en) | 2014-08-20 |
Family
ID=48409232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310053437.7A Active CN103110825B (en) | 2013-02-19 | 2013-02-19 | Medicinal composition for treating diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110825B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154255A (en) * | 1996-01-11 | 1997-07-16 | 严跃华 | Capsulized traditional Chinese proprietary medicine- |
| CN1173337A (en) * | 1995-04-18 | 1998-02-18 | 申志荣 | Granules medicament for effecting a radical cure of three types of diabetes |
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
-
2013
- 2013-02-19 CN CN201310053437.7A patent/CN103110825B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1173337A (en) * | 1995-04-18 | 1998-02-18 | 申志荣 | Granules medicament for effecting a radical cure of three types of diabetes |
| CN1154255A (en) * | 1996-01-11 | 1997-07-16 | 严跃华 | Capsulized traditional Chinese proprietary medicine- |
| CN102631526A (en) * | 2011-02-14 | 2012-08-15 | 王宇红 | Chinese medicinal composition for treating diabetes mellitus |
Non-Patent Citations (4)
| Title |
|---|
| 古瓦汤合补脾胃泻阴火升阳汤加味治疗2 型糖尿病86例;康小明;《陕西中医》;20081031;第29卷(第10期);1318-1319 * |
| 康小明.古瓦汤合补脾胃泻阴火升阳汤加味治疗2 型糖尿病86例.《陕西中医》.2008,第29卷(第10期),1318-1319. |
| 王桂玲.自拟抑肝降糖灵配合食疗治疗糖尿病.《中国社区医师(综合版)》.2005,第7卷(第23期),59. * |
| 邱若旗 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110825A (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104366636B (en) | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN100443111C (en) | A Chinese traditional medicine for treatment of hemorrhoid, anal fistula and anal fissure and their preparation methods | |
| CN105125885B (en) | It is a kind of to be used to prevent Chinese medicine composition of diabetes and preparation method thereof | |
| CN103110825B (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN101474258B (en) | Ficus microcarpa var.pusillifolia extract, extracting method and application of the extract | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| CN1726964A (en) | Chinese materia medica preparation for curing fracture and traumatic injury | |
| CN103099849B (en) | Medicinal composition for treatment of diabetes, preparation method and new application thereof | |
| CN1778350A (en) | Chinese medicine tablet for treating pelvic inflammatory disease | |
| CN103110698B (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN102218131B (en) | External Chinese herbal medicine composition for promoting tissue regeneration and knitting bones | |
| CN103110862B (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN103110721A (en) | Medicinal composition for treating diabetes | |
| CN100484561C (en) | Medicament composition for treating ulcer in alimentary canal and preparation method | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN103191170B (en) | Healthcare product for auxiliary treatment of type 2 diabetes, and preparation method thereof | |
| CN101112562B (en) | Chinese traditional medicine composition for treating hyperosteogeny | |
| CN100584364C (en) | A blood circulation-invigorating tendon-strengthening capsule and preparation process thereof | |
| CN100577195C (en) | Application of Chinese medicine composiiton in preparing medicine for treating salpingitis, oophoritic cyst, colpitis and cervicitis | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN100540038C (en) | The medicine of treatment hemorrhoid | |
| CN102247515A (en) | Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. Address before: 266103 Haier Road, Shandong, Qingdao, No. 1 Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: Zhengda Pharmaceutical (Qingdao) Co., Ltd. Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |